UPDATED INTERIM RESULTS OF A PHASE 1/2 STUDY OF BION-1301 IN PATIENTS WITH IGA NEPHROPATHY
Back
Abstract Number
WCN23-1175
Categories
Chronic Kidney Disease, Hypertension, Diabetes and CVD
Topic - Chronic Kidney Disease, Hypertension, Diabetes and CVD
Other CKD
Topic - AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
Topic - Kidney Failure (Former ESKD), incl. Dialysis, Transplantation, Conservative Care
Topic - Special Covid-19
Topic - Education
Abstract Title
UPDATED INTERIM RESULTS OF A PHASE 1/2 STUDY OF BION-1301 IN PATIENTS WITH IGA NEPHROPATHY
Co-authors
Barratt, J.(1)*;Kim, S.G.(2);Agha, I.(3);Kooienga, L.(4);Madan, A.(5);Ruiz-Ramon, P.(6);Thomas, H.(3);Workeneh, B.(7);Narayanan, R.(8);Sorensen, B.(9);Schwartz, B.M.(10);King, A.J.(11);Jones-Burton, C.(10);Lee, E.Y.(12);
ie:
Azwin Z.1, Siti Y.1, John D.2
Institution
(1)University Of Leicester, Department Of Cardiovascular Sciences, Leicester, United Kingdom;(2)Hallym University Sacred Heart Hospital, Nephrology Division, Gyeonggi-Do, South Korea;(3)Dallas Renal Group, Nephrology, Dallas, United States;(4)Colorado Kidney Care, Nephrology, Denver, United States;(5)Nephrology Associates Of Central Florida, Nephrology, Orlando, United States;(6)Florida Kidney Physicians, Nephrology, Tampa, United States;(7)Prolato Clinical Research Center, Nephrology, Houston, United States;(8)Chinook Therapeutics- Inc, Drug Metabolism And Pharmacokinetics, Seattle, United States;(9)Chinook Therapeutics- Inc, Biometrics, Seattle, United States;(10)Chinook Therapeutics- Inc, Clinical Development, Seattle, United States;(11)Chinook Therapeutics- Inc, Biology, Seattle, United States;(12)Soonchunhyang University Cheonan Hospital, Department Of Nephrology, Cheonan, South Korea;
E-Poster
https://storage.unitedwebnetwork.com/files/1041/b965fee9b0e33034e84b089b09d755c6.pdf
Audio File
if any